SCHEMBL13633567

SCHEMBL13633567

CN(C)CCOc1ccc(-c2ccnc(NC3CC(C)(C)NC(C)(C)C3)n2)s1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT3 Q9Y243 1/20 0.38
KCNH2 Q12809 2/20 0.35
CDK1 P06493 5/20 0.35
CCNB1 P14635 4/20 0.35
CCNB2 O95067 2/20 0.35
CCNB3 Q8WWL7 2/20 0.35
CDK4 P11802 4/20 0.34
CCNA2 P20248 3/20 0.34
CDK2 P24941 3/20 0.34
CCND1 P24385 2/20 0.34
CCNA1 P78396 2/20 0.34
IKBKB O14920 3/20 0.33
KDM4E B2RXH2 1/20 0.32
LMNA P02545 1/20 0.32
GAA P10253 1/20 0.32
MKNK1 Q9BUB5 1/20 0.32
EIF2AK2 P19525 1/20 0.32
ROCK2 O75116 2/20 0.31
AURKA O14965 1/20 0.31
TTK P33981 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4488220 0.99 AKT3 (0.37) AKT3KCNH2CDK1CCNB1CCNB2
SCHEMBL3471003 0.89 KCNH2 (0.37) KCNH2CDK1CCNB1CCNB2CCNB3
SCHEMBL3476364 0.88 CDK4 (0.37) AKT3KCNH2CDK1CCNB1CCNB2
SCHEMBL13638464 0.87 AKT3 (0.35) AKT3CDK1CCNB1CCNB2CCNB3
SCHEMBL3478297 0.84 AKT3 (0.39) AKT3KCNH2CDK1CCNB1CCNB2
SCHEMBL3477117 0.82 SLC2A1 (0.42) AKT3KCNH2CDK1CCNB1CDK4
SCHEMBL4479727 0.80 KCNH2 (0.36) AKT3KCNH2CDK1CCNB1CCNB2
SCHEMBL3471517 0.78 ALDH1A1 (0.35) AKT3KCNH2CDK1CCNB1CDK4
SCHEMBL4491192 0.78 IKBKB (0.41) KCNH2CDK1CCNB1CCNB2CCNB3
SCHEMBL4487841 0.78 KCNH2 (0.40) AKT3KCNH2CDK1CCNB1CCNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1615898-B1 2-Aminopyrimidine derivatives and their medical use NOVARTIS AG (CH) 2014-10-29 EP claimed
EP-1615898-B1 2-Aminopyrimidine derivatives and their medical use NOVARTIS AG (CH) 2014-10-29 EP disclosed
EP-1615898-B1 2-Aminopyrimidine derivatives and their medical use NOVARTIS AG (CH) 2014-10-29 EP disclosed
US-7615562-B2 Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents NOVARTIS AG (CH) 2009-11-10 US disclosed
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use NOVARTIS AG (CH) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use TPMT, IKBKB, CHUK AKT3 678/4885KCNH2 3073/4885CDK1 555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.